TPM3 and non-small cell lung carcinoma: Repotrectinib is also used to treat adult patients with ROS1 fusion-positive locally advanced or metastatic NSCLC and patients with NTRK fusion-positive advanced solid tumors who have received one or two frontline tropomyosin receptor kinase (TRK) or TKI therapies without a satisfactory response or alternative options.